Mesoblast Secures Regenerative Advanced Therapy Designation From US FDA for Cellular Therapy Product; Shares Hit Near 3.5-Year High
Mesoblast Secures Regenerative Advanced Therapy Designation From US FDA for Cellular Therapy Product; Shares Hit Near 3.5-Year High
mesoblast获得美国FDA对细胞治疗产品的再生爱文思控股疗法资格；股价接近3.5年的高点
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间